Novartis Pharmaceuticals – FLT3-mutated Acute Myeloid Leukemia

Access Program Information

The purpose of this study is to gather and evaluate additional safety data on the
combination of midostaurin and standard of care for adult patients with newly diagnosed
Fms-like tyrosine kinase receptor (FLT3) mutated Acute Myeloid Leukemia (AML) who are
eligible for standard induction and consolidation chemotherapy and are without satisfactory
treatment alternatives prior to the commercial availability* and reimbursement of
midostaurin during the regulatory approval process